with Rheumatoid Arthritis
Study Overview
The AstraZeneca “LaunchPAD-RA” study is testing a potential new, injectable drug (AZD1163) to see if it helps adults with rheumatoid arthritis who have not improved with their usual treatments.
Study Highlights
1. Coverage of all study-related costs
a. All study-related costs and care are covered
b. You may be compensated for travel
2. Participation in the study will last up to 1 year (approximately 52 weeks)
3. The investigational medication (AZD1163) will be given as an injection under the skin (subcutaneous (SC)) once weekly for the first 4 weeks, then every 2 weeks.
Who Can Participate in the LaunchPAD-RA Study?
Who Can Participate in the LaunchPAD-RA Study?
What Should I Expect?
Screening Visit
Before you begin the study drug, AZD1163, or placebo, you will complete screening – including consent, medical history, and testing to determine if the study is right for you.
Randomization Visit
Participants are randomly assigned (75/25) to receive either the investigational study medication/injection or a matching placebo with no active medicine.
Treatment Phase
Should you qualify, your participation may last up to ~24 weeks. You’ll take either Investigational study drug (AZD1163) or matching placebo alongside your regular rheumatoid arthritis medication. Participation is voluntary, and you can stop taking it at any time.